ClinicalTrials.gg
CompletedNCT01917331TRILOGYUpdated Jul 20, 2026Results posted

Efficacy of Fixed Combination of Beclometasone + Formoterol + Glycopyrrolate Versus Foster® in COPD

A Phase 3 interventional study of Beclometasone/Formoterol/Glycopyrrolate and Beclometasone/Formoterol in Chronic Obstructive Pulmonary Disease (COPD), sponsored by Chiesi Farmaceutici S.p.A.. Completed at 1 site in Hungary. Open to participants aged 40 Years and older. Per ClinicalTrials.gov, last updated 2026-07-20.

Sponsored by Chiesi Farmaceutici S.p.A. · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
1,368
Allocation
Randomized
Ages
40 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 13 studies testing beclomethasone in Pulmonary Disease, Chronic Obstructive — none open to participants now, none under way, none of them phase 3. Beclomethasone · Pulmonary Disease, Chronic Obstructive.

Enrollment
Largest of 13
1,368 · median 24
Started
2014
with 2 others
Phase 3
3 of 13
none open now
Registered
6th of 13
by date
Lead sponsor
6 of 13
Chiesi Farmaceutici S.p.A.

Among the 13 studies testing beclomethasone in Pulmonary Disease, Chronic Obstructive, this one has the largest enrollment, is one of 3 that started in 2014, is one of 3 in phase 3, and was the 6th registered.

Pulmonary Disease, Chronic Obstructive

5,523 studies on the registry are indexed under Pulmonary Disease, Chronic Obstructive; 857 are open to participants now.

Browse Pulmonary Disease, Chronic Obstructive studies →

Open to participants now

None of the 13 studies testing beclomethasone in Pulmonary Disease, Chronic Obstructive is open now. The open studies under Pulmonary Disease, Chronic Obstructive, anywhere →

About beclomethasone

Beclomethasone: first FDA approval 1976 (VANCERIL), first EMA approval 2017. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 557 Pulmonary Disease, Chronic Obstructive studies recruiting now, 306 (55%) set no upper age limit and 82 (15%) stop at 75 or younger; 29 take children under 18; 89 take healthy volunteers.

This study: 40 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Download CSVNarrow it in search →With an account: the 13 studies testing beclomethasone in Pulmonary Disease, Chronic Obstructive as a file.
02

Study summary

Randomized,double-blind,multicenter,multinational,parallel-group,Phase III study to demonstrate the superiority of the triple fixed combination of beclometasone + formoterol + glycopyrrolate (BDP/FF/GB) administered via pressurised metered dose inhaler (pMDI) over the equivalent dose of Foster® (beclometasone dipropionate (BDP) / formoterol fumarate (FF), in patients diagnosed with chronic obstructive pulmonary disease (COPD) after 52 weeks of treatment.

Read the detailed description

This 52-week randomised 2 parallel groups study evaluated the superiority of fixed triple therapy with Inhaled Corticosteroid (ICS) / Long-Acting β2-Agonist (LABA) / Long-Acting Muscarinic Antagonist (LAMA) compared with ICS/LABA in patients with severe to very severe diagnosed of COPD.

Patients' eligibility was checked during the screening visit including the review of medical history, spirometry assessments, routine labs, physical examination, 12-lead electrocardiogram (ECG), vital signs measurement, prior to entering a 2-week open-label run-in period with BDP/FF to establish a baseline.

After the run-in period, eligible patients were randomised, to either fixed triple therapy BDP/FF/GB or BDP/FF treatment group. During the 52-week treatment period, patients who completed the study did have 5 subsequent visits post randomisation scheduled respectively after 4, 12, 26, 40, and 52 weeks of treatment. During these visits, pre-dose and post-dose spirometry, 12-lead ECG, vital signs, and dyspnoea assessments were performed. Rescue medication use, compliance with the treatment, and EXACT-PRO questionnaire [EXAcerbations of Chronic Obstructive Pulmonary Disease Tool (EXACT): a patient-reported outcome (PRO)] were recorded daily (via an electronic diary) during the run-in and randomised treatment periods.

For pharmacovigilance purposes, adverse events (AE) were recorded from the time of patient informed consent signature until subject's study participation ended (Week 52 or early discontinuation).

03

Conditions studied

  • Chronic Obstructive Pulmonary Disease (COPD)

Keywords

  • spirometry
  • severe COPD
  • lung disease
  • fixed combination treatment
  • COPD
  • Chronic Obstructive Pulmonary Disease
04

Who can participate

Ages eligible
40 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Male or female adults aged ≥ 40 years with a diagnosis of
  • Current smokers or ex-smokers
  • A post-bronchodilator Forced Expiratory Volume in the 1st Second () \< 50% of the predicted normal value and a post- bronchodilator FEV1/ Forced Vital Capacity (FVC) \< 0.7
  • At least one exacerbation in the 12 months preceding the screening visit

Exclusion criteria

Exclusion Criteria:

  • Pregnant or lactating women
  • Diagnosis of asthma or history of allergic rhinitis or atopy
  • Patients treated with non-cardioselective β-blockers in the month preceding the screening visit
  • Patients treated for exacerbations in the 4 weeks prior to screening visit
  • Patients treated with long-acting antihistamines unless taken at stable regimen at least 2 months prior to screening and to be maintained constant during the study or if taken as PRN
  • Patients requiring long term (at least 12 hours daily) oxygen therapy for chronic hypoxemia
  • Known respiratory disorders other than
  • Patients who have cardiovascular condition
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

COPD

Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.

FEV1

From a breathing test (spirometry): how much air you can blow out in the first second. Often given as a percentage of what is expected for your age, height and sex.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
1,368 participants (actual)

Study arms

  • Experimental
    Beclometasone/Formoterol/Glycopyrrolate

    CHF 5993 pMDI 100/6/12.5 µg 2 inhalations bid

    Drug: Beclometasone/Formoterol/Glycopyrrolate

  • Active comparator
    Beclometasone/Formoterol

    Foster® 100/6 µg 2 inhalations bid

    Drug: Beclometasone/Formoterol

Interventions

  • DrugBeclometasone/Formoterol/Glycopyrrolate

    Drug pages: Beclomethasone · Formoterol · Glycopyrrolate

    Active drug tested

    Also known as: BDP/FF/GB or CHF 5993 pMDI 100/6/12.5 µg

  • DrugBeclometasone/Formoterol

    Drug pages: Beclomethasone · Formoterol

    Active comparator

    Also known as: Foster® or CHF 1535 pMDI 100/6 µg

06

What researchers measure

Primary outcomes

  1. 1_Change From Baseline in Pre-dose Morning Forced Expiratory Volume in the 1st Second (FEV1) -- at Week 26

    Changes from baseline in pre-dose morning FEV1 to visit at Week 26. FEV1=Forced expiratory volume in the 1st second. It is the volume of air that can be forced out in one second after taking a deep breath.

    Time frame: Baseline (Week 0), Week 26.

  2. 2_Change From Baseline in 2-hour Post-dose FEV1 -- at Week 26

    Change from baseline in 2-hour post-dose FEV1, at Week 26. FEV1=Forced expiratory volume in the 1st second. It is the volume of air that can be forced out in one second after taking a deep breath.

    Time frame: Baseline (Week 0) to 2-hour post-dose at Week 26.

  3. 3_Transition Dyspnoea Index (TDI) Focal Score -- at Week 26

    Transition Dyspnoea Index (TDI) focal score is a symptom-based variable tool, used to assess breathlessness and the impact of intervention. BDI/TDI is a clinical rating method based on a validated tool that measures the impact of dyspnoea based on 3 domains: functional impairment, magnitude of task, and magnitude of effort. BDI focal score is the baseline value from which TDI focal score is assessed. BDI scores range from 0 (very severe impairment) to 4 (no impairment) for each domain with the baseline focal score consisting of the sum of each domain (i.e. from 0 to 12). Change from baseline in dyspnoea severity was measured using the TDI. TDI score ranges from -3 (major deterioration) to +3 (major improvement) for each domain, with the TDI focal score consisting of the sum of each domain (i.e. from -9 to +9). A higher total score indicates improvement, while a lower or negative score indicates worsening symptoms. BDI=Baseline Dyspnoea Index TDI=Transition Dyspnoea Index

    Time frame: Baseline (Week 0), Week 26.

Secondary outcomes

  1. 4_Change From Baseline in Pre-dose Morning FEV1 -- at All the Other Clinic Visits

    Change from baseline in pre-dose morning FEV1, at all the other clinic visits. Please note: results at visit Week 26, are presented as the primary outcome measure #1 for this study. FEV1=Forced expiratory volume in the 1st second. It is the volume of air that can be forced out in one second after taking a deep breath.

    Time frame: Baseline (Week 0), Week 4. 12, 40, 52.

  2. 5_Change From Baseline to the Average in Pre-dose Morning FEV1 -- Over the Treatment Period

    Changes from baseline for the average in pre-dose morning FEV1 over the treatment period. FEV1=Forced expiratory volume in the 1st second. It is the volume of air that can be forced out in one second after taking a deep breath.

    Time frame: Baseline (Week 0), Week 4, 12, 26, 40, 52.

  3. 6_Number of Participants Defined as Responders Wrt. to FEV1 -- Change From Baseline in Pre-dose Morning FEV1 ≥100 mL -- at Week 26 and Week 52

    Number of participants defined as responders wrt. to FEV1 -- at Week 26 and Week 52. FEV1 response was defined as a change from baseline in pre-dose morning FEV1 of ≥100 mL. If the change from baseline was \<100 mL, the patient was classified as a non-responder in terms of FEV1. Subjects with missing pre-dose morning FEV1 value at the pre-specified tested time points were also classified as non-responders. FEV1=Forced expiratory volume in the 1st second. It is the volume of air that can be forced out in one second after taking a deep breath.

    Time frame: Baseline (Week 0), Week 26, Week 52.

  4. 7_Change From Baseline in 2-hour Post-dose of FEV1 -- at All the Other Clinic Visits

    Change from baseline in 2-hour post-dose of FEV1, at all the other clinic visits. Please note: a) results at visit Week 26, are presented as the primary outcome measure #2 for this study; b) for Week 0, the measurement shown in the results table below was made 2 h after the baseline measurement i.e. pre-treatment at study baseline. FEV1=Forced expiratory volume in the 1st second. It is the volume of air that can be forced out in one second after taking a deep breath.

    Time frame: Baseline (Week 0), Week 4, 12, 40, 52.

  5. 8_Change From Pre-dose to 2-hour Post-dose FEV1 -- at All Study Visits

    Change from pre-dose to 2-hour post-dose value of FEV1, at study visits on Week 4, 12, 26, 40, and 52. FEV1=Forced expiratory volume in the 1st second. It is the volume of air that can be forced out in one second after taking a deep breath.

    Time frame: Week 4, 12, 26, 40, 52.

  6. 9_Transition Dyspnoea Index (TDI) Focal Score -- at All Study Visits

    TDI focal score is a symptom-based tool, used to assess breathlessness and the impact of intervention. BDI/TDI is a clinical rating method based on a validated tool that measures the impact of dyspnoea on 3 domains: functional impairment, magnitude of task, and magnitude of effort. TDI tool and its scoring system are defined in the outcome measure #3 of this PRS study entry. Please note: Results at Week 26, are presented as the primary outcome measure #3 for this PRS study entry. BDI=Baseline Dyspnoea Index TDI=Transition Dyspnoea Index

    Time frame: Baseline (Week 0), Week 4, 12, 40, 52.

  7. 10_Number of Participants With Transition Dyspnoea Index (TDI) Response (Focal Score ≥1) -- at Week 26 and Week 52

    Number of participants with transition dyspnoea index (TDI) response (focal score ≥1) -- at Week 26 and Week 52. TDI tool and its scoring system are defined in the outcome measure #3 of this PRS study entry. TDI response was defined as a TDI focal score of ≥1. If the TDI focal score was \<1, the patient was classified as a non-responder in terms of TDI. Patients with missing TDI focal score at the pre-specified tested time points were also classified as non-responders.

    Time frame: Week 26, Week 52.

  8. 11a_Change From Baseline in Saint George's Respiratory Questionnaire (SGRQ) -- at All Study Visits: Total Score

    Change from baseline in Saint George's respiratory questionnaire (SGRQ) Total score. SGRQ is a 76-item questionnaire developed to measure health in chronic airflow limitation. SGRQ consists of scores from three component that are used to calculate the total score: Symptoms, Activity, and Impacts on daily life. SGRQ questionnaire was completed by the patient at all study visits (Week 0 baseline, and Week 4, 12, 26, 40, 52). The Total score range is from 0 to 100 (0=Best, 100=Worst); lower scores correspond to better health. SGRQ questionnaire was completed by the patient at all study visits (Week 0 baseline, 4, 12, 26, 40, 52).

    Time frame: Baseline (Week 0), Week 4, 12, 26, 40, 52.

  9. 11b_Change From Baseline in Saint George's Respiratory Questionnaire (SGRQ) -- at All Study Visits: Symptoms Score

    Change from baseline in Saint George's respiratory questionnaire (SGRQ) -- Symptoms Score. SGRQ is a questionnaire developed to measure health in chronic airflow limitation. SGRQ questionnaire was completed by the patient at all study visits (Week 0 baseline, 4, 12, 26, 40, 52). Result show the Saint George's Respiratory Questionnaire (SGRQ) as change from baseline for the domain Symptoms. The Symptoms score is calculated on a scale of 0 to 100. A score of 0 indicates no impairment (best health); a score of 100 indicates the worst possible health status.

    Time frame: Baseline (Week 0), Week 4, 12, 26, 40, 52.

  10. 11c_Change From Baseline in Saint George's Respiratory Questionnaire (SGRQ) -- at All Study Visits: Impacts Score

    Saint George's respiratory questionnaire (SGRQ) -- Impacts Score. SGRQ is a questionnaire developed to measure health in chronic airflow limitation. SGRQ questionnaire was completed by the patient at all study visits (Week 0 baseline, 4, 12, 26, 40, 52). Result show the Saint George's Respiratory Questionnaire (SGRQ) as change from baseline for the domain Impacts. The Impact score is calculated on a scale of 0 to 100. A score of 0 indicates no impairment (best health); a score of 100 indicates the worst possible health status.

    Time frame: Baseline (Week 0), Week 4, 12, 26, 40, 52.

  11. 11d_Change From Baseline in Saint George's Respiratory Questionnaire (SGRQ) -- at All Study Visits: Activity Score

    Saint George's respiratory questionnaire (SGRQ) -- Activity score. SGRQ is a questionnaire developed to measure health in chronic airflow limitation. SGRQ questionnaire was completed by the patient at all study visits (Week 0 baseline, 4, 12, 26, 40, 52). Result show the Saint George's Respiratory Questionnaire (SGRQ) as change from baseline for the domain Activity. The Activity score is calculated on a scale of 0 to 100. A score of 0 indicates no impairment (best health); a score of 100 indicates the worst possible health status.

    Time frame: Baseline (Week 0), Week 4, 12, 26, 40, 52.

  12. 12_Number of Participants With Saint George's Respiratory Questionnaire (SGRQ) Response (Change From Baseline in Total Score ≤-4) -- at Week 26 and Week 52

    Number of participants with Saint George's Respiratory Questionnaire (SGRQ) response, defined as a change from baseline in SGRQ total score ≤ -4, at Week 26 and Week 52. If the change from baseline was \> -4, the patient was assessed as a non-responder in terms of SGRQ. Patients with missing change from baseline at the pre-specified tested time points were also classified as non-responders. Results shown represent the number of responder participants in terms of SGRQ, for the comparison of CHF 5993 pMDI versus CHF 1535 pMDI.

    Time frame: Baseline (Week 0), Week 26, Week 52.

  13. 13a_Change From Baseline for Percentage of Days Without Intake of Rescue Medication -- Over Entire Treatment Period (52 Weeks of Treatment)

    Days WITHOUT intake of rescue medication. Change from baseline to each inter-visit period and for the entire treatment period (Week 1-52) in the percentage of days without intake of rescue medication.

    Time frame: Baseline (Week 0) to Week 4, 12, 26, 40, 52.

  14. 13b_Change From Baseline for the Average Use of Rescue Medication -- Over Entire Treatment Period (52 Weeks of Treatment)

    Average use of rescue medication, over the entire treatment period (52 Weeks of treatment). Change from baseline to each inter-visit period and for the entire treatment period (Week 1-52) in the average use of rescue medication (number of puffs/day).

    Time frame: Baseline (Week 0) to Week 4, 12, 26, 40, 52.

  15. 14_Rate of Moderate and Severe Chronic Obstructive Pulmonary Disease (COPD) Exacerbation Rate -- Over Entire Treatment Period (52 Weeks of Treatment)

    Rate of moderate AND severe COPD exacerbations over the entire treatment period of treatment (52 weeks). COPD=Chronic obstructive pulmonary disease

    Time frame: Baseline (Week 0) to Week 52 (entire treatment period).

  16. 15_First Occurrence of All Moderate or Severe Chronic Obstructive Pulmonary Disease (COPD) Exacerbation

    First occurrence of at least 1 moderate OR severe COPD exacerbation. First occurrence was analysed by Cox regression as time to first exacerbation and reported as hazard ratio. COPD=Chronic obstructive pulmonary disease

    Time frame: Baseline (Week 0), Week 52.

07

Results

Posted Jun 3, 2026

Participant flow

Participant flow — Overall Study
MilestoneCHF 5993 pMDI -- Beclometasone/Formoterol/GlycopyrrolateFoster® pMDI -- Beclometasone/Formoterol
Started687681
Completed602579
Not completed85102
Withdrew: Adverse event, serious fatal1315
Withdrew: Withdrawal by subject4554
Withdrew: Adverse event2017
Withdrew: Lost to follow-up25
Withdrew: Lack of efficacy36
Withdrew: Protocol violation23
Withdrew: Physician decision01
Withdrew: Moved to another state; could not attend study visits.01

Outcome measures

Primary1_Change From Baseline in Pre-dose Morning Forced Expiratory Volume in the 1st Second (FEV1) -- at Week 26

Changes from baseline in pre-dose morning FEV1 to visit at Week 26. FEV1=Forced expiratory volume in the 1st second. It is the volume of air that can be forced out in one second after taking a deep breath.

Time frame:
Baseline (Week 0), Week 26.
Reported as:
Least squares mean · litre
1_Change From Baseline in Pre-dose Morning Forced Expiratory Volume in the 1st Second (FEV1) -- at Week 26
litreCHF 5993 pMDICHF 1535 pMDI Foster®
1_Change From Baseline in Pre-dose Morning Forced Expiratory Volume in the 1st Second (FEV1) -- at Week 260.082 (0.062 to 0.102)0.001 (-0.019 to 0.021)
Statistical analysis
  • CHF 5993 pMDI vs CHF 1535 pMDI Foster® · Linear Mixed Model for Repeated Measures · p = < 0.001 · Adjusted mean difference: 0.081 · 95% CI 0.052 to 0.109
Primary2_Change From Baseline in 2-hour Post-dose FEV1 -- at Week 26

Change from baseline in 2-hour post-dose FEV1, at Week 26. FEV1=Forced expiratory volume in the 1st second. It is the volume of air that can be forced out in one second after taking a deep breath.

Time frame:
Baseline (Week 0) to 2-hour post-dose at Week 26.
Reported as:
Least squares mean · litre
2_Change From Baseline in 2-hour Post-dose FEV1 -- at Week 26
litreCHF 5993 pMDICHF 1535 pMDI Foster®
2_Change From Baseline in 2-hour Post-dose FEV1 -- at Week 260.261 (0.240 to 0.283)0.145 (0.123 to 0.166)
Statistical analysis
  • CHF 5993 pMDI vs CHF 1535 pMDI Foster® · Linear Mixed Model for Repeated Measures · p = < 0.001 · Adjusted mean difference: 0.117 · 95% CI 0.086 to 0.147
Primary3_Transition Dyspnoea Index (TDI) Focal Score -- at Week 26

Transition Dyspnoea Index (TDI) focal score is a symptom-based variable tool, used to assess breathlessness and the impact of intervention. BDI/TDI is a clinical rating method based on a validated tool that measures the impact of dyspnoea based on 3 domains: functional impairment, magnitude of task, and magnitude of effort. BDI focal score is the baseline value from which TDI focal score is assessed. BDI scores range from 0 (very severe impairment) to 4 (no impairment) for each domain with the baseline focal score consisting of the sum of each domain (i.e. from 0 to 12). Change from baseline in dyspnoea severity was measured using the TDI. TDI score ranges from -3 (major deterioration) to +3 (major improvement) for each domain, with the TDI focal score consisting of the sum of each domain (i.e. from -9 to +9). A higher total score indicates improvement, while a lower or negative score indicates worsening symptoms. BDI=Baseline Dyspnoea Index TDI=Transition Dyspnoea Index

Time frame:
Baseline (Week 0), Week 26.
Reported as:
Least squares mean · score on a scale
3_Transition Dyspnoea Index (TDI) Focal Score -- at Week 26
score on a scaleCHF 5993 pMDICHF 1535 pMDI Foster®
3_Transition Dyspnoea Index (TDI) Focal Score -- at Week 261.71 (1.50 to 1.92)1.50 (1.29 to 1.71)
Statistical analysis
  • CHF 5993 pMDI vs CHF 1535 pMDI Foster® · Linear Mixed Model for Repeated Measures · p = = 0.160 · Adjusted mean difference: 0.21 · 95% CI -0.08 to 0.51
Secondary4_Change From Baseline in Pre-dose Morning FEV1 -- at All the Other Clinic Visits

Change from baseline in pre-dose morning FEV1, at all the other clinic visits. Please note: results at visit Week 26, are presented as the primary outcome measure #1 for this study. FEV1=Forced expiratory volume in the 1st second. It is the volume of air that can be forced out in one second after taking a deep breath.

Time frame:
Baseline (Week 0), Week 4. 12, 40, 52.
Reported as:
Least squares mean · litre
4_Change From Baseline in Pre-dose Morning FEV1 -- at All the Other Clinic Visits
litreCHF 5993 pMDICHF 1535 pMDI Foster®
Week 40.093 (0.076 to 0.109)0.022 (0.005 to 0.039)
Week 120.078 (0.060 to 0.096)0.010 (-0.008 to 0.028)
Week 400.095 (0.073 to 0.116)0.018 (-0.004 to 0.040)
Week 520.071 (0.050 to 0.093)0.008 (-0.014 to 0.030)
Statistical analysis
  • CHF 5993 pMDI vs CHF 1535 pMDI Foster® · Linear Mixed Model for Repeated Measures · p = < 0.001 · Adjusted mean difference: 0.071 · 95% CI 0.047 to 0.094
  • CHF 5993 pMDI vs CHF 1535 pMDI Foster® · Linear Mixed Model for Repeated Measures · p = < 0.001 · Adjusted mean difference: 0.068 · 95% CI 0.042 to 0.094
  • CHF 5993 pMDI vs CHF 1535 pMDI Foster® · Linear Mixed Model for Repeated Measures · p = < 0.001 · Adjusted mean difference: 0.077 · 95% CI 0.046 to 0.108
  • CHF 5993 pMDI vs CHF 1535 pMDI Foster® · Linear Mixed Model for Repeated Measures · p = < 0.001 · Adjusted mean difference: 0.063 · 95% CI 0.032 to 0.094
Secondary5_Change From Baseline to the Average in Pre-dose Morning FEV1 -- Over the Treatment Period

Changes from baseline for the average in pre-dose morning FEV1 over the treatment period. FEV1=Forced expiratory volume in the 1st second. It is the volume of air that can be forced out in one second after taking a deep breath.

Time frame:
Baseline (Week 0), Week 4, 12, 26, 40, 52.
Reported as:
Least squares mean · litre
5_Change From Baseline to the Average in Pre-dose Morning FEV1 -- Over the Treatment Period
litreCHF 5993 pMDICHF 1535 pMDI Foster®
5_Change From Baseline to the Average in Pre-dose Morning FEV1 -- Over the Treatment Period0.084 (0.067 to 0.100)0.012 (-0.005 to 0.029)
Statistical analysis
  • CHF 5993 pMDI vs CHF 1535 pMDI Foster® · Linear Mixed Model for Repeated Measures · p = < 0.001 · Adjusted mean difference: 0.072 · 95% CI 0.048 to 0.096
Secondary6_Number of Participants Defined as Responders Wrt. to FEV1 -- Change From Baseline in Pre-dose Morning FEV1 ≥100 mL -- at Week 26 and Week 52

Number of participants defined as responders wrt. to FEV1 -- at Week 26 and Week 52. FEV1 response was defined as a change from baseline in pre-dose morning FEV1 of ≥100 mL. If the change from baseline was \<100 mL, the patient was classified as a non-responder in terms of FEV1. Subjects with missing pre-dose morning FEV1 value at the pre-specified tested time points were also classified as non-responders. FEV1=Forced expiratory volume in the 1st second. It is the volume of air that can be forced out in one second after taking a deep breath.

Time frame:
Baseline (Week 0), Week 26, Week 52.
Reported as:
Count of participants · Participants
6_Number of Participants Defined as Responders Wrt. to FEV1 -- Change From Baseline in Pre-dose Morning FEV1 ≥100 mL -- at Week 26 and Week 52
ParticipantsCHF 5993 pMDICHF 1535 pMDI Foster®
Week 26287165
Week 52259158
Statistical analysis
  • CHF 5993 pMDI vs CHF 1535 pMDI Foster® · Logistic model · p = < 0.001 · Odds ratio (or): 2.299 · 95% CI 1.817 to 2.910
  • CHF 5993 pMDI vs CHF 1535 pMDI Foster® · Logistic model · p = < 0.001 · Odds ratio (or): 2.061 · 95% CI 1.621 to 2.620
Secondary7_Change From Baseline in 2-hour Post-dose of FEV1 -- at All the Other Clinic Visits

Change from baseline in 2-hour post-dose of FEV1, at all the other clinic visits. Please note: a) results at visit Week 26, are presented as the primary outcome measure #2 for this study; b) for Week 0, the measurement shown in the results table below was made 2 h after the baseline measurement i.e. pre-treatment at study baseline. FEV1=Forced expiratory volume in the 1st second. It is the volume of air that can be forced out in one second after taking a deep breath.

Time frame:
Baseline (Week 0), Week 4, 12, 40, 52.
Reported as:
Least squares mean · litre
7_Change From Baseline in 2-hour Post-dose of FEV1 -- at All the Other Clinic Visits
litreCHF 5993 pMDICHF 1535 pMDI Foster®
Week 0 (measurement made 2 h after baseline)0.215 (0.203 to 0.228)0.138 (0.126 to 0.150)
Week 40.268 (0.250 to 0.286)0.153 (0.135 to 0.171)
Week 120.261 (0.241 to 0.281)0.146 (0.125 to 0.166)
Week 400.253 (0.230 to 0.275)0.150 (0.127 to 0.174)
Week 520.249 (0.226 to 0.273)0.146 (0.122 to 0.170)
Statistical analysis
  • CHF 5993 pMDI vs CHF 1535 pMDI Foster® · Linear Mixed Model for Repeated Measures · p = < 0.001 · Adjusted mean difference: 0.077 · 95% CI 0.060 to 0.095
  • CHF 5993 pMDI vs CHF 1535 pMDI Foster® · Linear Mixed Model for Repeated Measures · p = < 0.001 · Adjusted mean difference: 0.116 · 95% CI 0.090 to 0.141
  • CHF 5993 pMDI vs CHF 1535 pMDI Foster® · Linear Mixed Model for Repeated Measures · p = < 0.001 · Adjusted mean difference: 0.116 · 95% CI 0.087 to 0.144
  • CHF 5993 pMDI vs CHF 1535 pMDI Foster® · Linear Mixed Model for Repeated Measures · p = < 0.001 · Adjusted mean difference: 0.102 · 95% CI 0.070 to 0.135
  • CHF 5993 pMDI vs CHF 1535 pMDI Foster® · Linear Mixed Model for Repeated Measures · p = < 0.001 · Adjusted mean difference: 0.103 · 95% CI 0.069 to 0.137
Secondary8_Change From Pre-dose to 2-hour Post-dose FEV1 -- at All Study Visits

Change from pre-dose to 2-hour post-dose value of FEV1, at study visits on Week 4, 12, 26, 40, and 52. FEV1=Forced expiratory volume in the 1st second. It is the volume of air that can be forced out in one second after taking a deep breath.

Time frame:
Week 4, 12, 26, 40, 52.
Reported as:
Least squares mean · liter
8_Change From Pre-dose to 2-hour Post-dose FEV1 -- at All Study Visits
literCHF 5993 pMDICHF 1535 pMDI Foster®
Week 40.177 (0.165 to 0.189)0.130 (0.118 to 0.143)
Week 120.183 (0.171 to 0.194)0.138 (0.126 to 0.149)
Week 260.180 (0.169 to 0.192)0.149 (0.138 to 0.161)
Week 400.159 (0.147 to 0.171)0.138 (0.125 to 0.150)
Week 520.180 (0.167 to 0.193)0.146 (0.133 to 0.159)
Statistical analysis
  • CHF 5993 pMDI vs CHF 1535 pMDI Foster® · ANCOVA · p = < 0.001 · Adjusted mean difference: 0.046 · 95% CI 0.029 to 0.064
  • CHF 5993 pMDI vs CHF 1535 pMDI Foster® · ANCOVA · p = < 0.001 · Adjusted mean difference: 0.045 · 95% CI 0.029 to 0.062
  • CHF 5993 pMDI vs CHF 1535 pMDI Foster® · ANCOVA · p = < 0.001 · Adjusted mean difference: 0.031 · 95% CI 0.015 to 0.047
  • CHF 5993 pMDI vs CHF 1535 pMDI Foster® · ANCOVA · p = = 0.013 · Adjusted mean difference: 0.022 · 95% CI 0.005 to 0.039
  • CHF 5993 pMDI vs CHF 1535 pMDI Foster® · ANCOVA · p = < 0.001 · Adjusted mean difference: 0.034 · 95% CI 0.016 to 0.052
Secondary9_Transition Dyspnoea Index (TDI) Focal Score -- at All Study Visits

TDI focal score is a symptom-based tool, used to assess breathlessness and the impact of intervention. BDI/TDI is a clinical rating method based on a validated tool that measures the impact of dyspnoea on 3 domains: functional impairment, magnitude of task, and magnitude of effort. TDI tool and its scoring system are defined in the outcome measure #3 of this PRS study entry. Please note: Results at Week 26, are presented as the primary outcome measure #3 for this PRS study entry. BDI=Baseline Dyspnoea Index TDI=Transition Dyspnoea Index

Time frame:
Baseline (Week 0), Week 4, 12, 40, 52.
Reported as:
Least squares mean · score on a scale
9_Transition Dyspnoea Index (TDI) Focal Score -- at All Study Visits
score on a scaleCHF 5993 pMDICHF 1535 pMDI Foster®
Week 41.54 (1.35 to 1.72)1.12 (0.94 to 1.31)
Week 121.77 (1.58 to 1.97)1.39 (1.19 to 1.58)
Week 401.80 (1.58 to 2.01)1.65 (1.43 to 1.86)
Week 522.03 (1.81 to 2.25)1.81 (1.59 to 2.04)
Statistical analysis
  • CHF 5993 pMDI vs CHF 1535 pMDI Foster® · Linear Mixed Model for Repeated Measures · p = = 0.002 · Adjusted mean difference: 0.41 · 95% CI 0.15 to 0.68
  • CHF 5993 pMDI vs CHF 1535 pMDI Foster® · Linear Mixed Model for Repeated Measures · p = = 0.007 · Adjusted mean difference: 0.38 · 95% CI 0.11 to 0.66
  • CHF 5993 pMDI vs CHF 1535 pMDI Foster® · Linear Mixed Model for Repeated Measures · p = = 0.343 · Adjusted mean difference: 0.15 · 95% CI -0.16 to 0.45
  • CHF 5993 pMDI vs CHF 1535 pMDI Foster® · Linear Mixed Model for Repeated Measures · p = = 0.186 · Adjusted mean difference: 0.21 · 95% CI -0.10 to 0.53
Secondary10_Number of Participants With Transition Dyspnoea Index (TDI) Response (Focal Score ≥1) -- at Week 26 and Week 52

Number of participants with transition dyspnoea index (TDI) response (focal score ≥1) -- at Week 26 and Week 52. TDI tool and its scoring system are defined in the outcome measure #3 of this PRS study entry. TDI response was defined as a TDI focal score of ≥1. If the TDI focal score was \<1, the patient was classified as a non-responder in terms of TDI. Patients with missing TDI focal score at the pre-specified tested time points were also classified as non-responders.

Time frame:
Week 26, Week 52.
Reported as:
Count of participants · Participants
10_Number of Participants With Transition Dyspnoea Index (TDI) Response (Focal Score ≥1) -- at Week 26 and Week 52
ParticipantsCHF 5993 pMDICHF 1535 pMDI Foster®
Week 26394352
Week 52370354
Statistical analysis
  • CHF 5993 pMDI vs CHF 1535 pMDI Foster® · Logistic model · p = = 0.027 · Odds ratio (or): 1.280 · 95% CI 1.029 to 1.594
  • CHF 5993 pMDI vs CHF 1535 pMDI Foster® · Logistic model · p = = 0.430 · Odds ratio (or): 1.093 · 95% CI 0.877 to 1.362
Secondary11a_Change From Baseline in Saint George's Respiratory Questionnaire (SGRQ) -- at All Study Visits: Total Score

Change from baseline in Saint George's respiratory questionnaire (SGRQ) Total score. SGRQ is a 76-item questionnaire developed to measure health in chronic airflow limitation. SGRQ consists of scores from three component that are used to calculate the total score: Symptoms, Activity, and Impacts on daily life. SGRQ questionnaire was completed by the patient at all study visits (Week 0 baseline, and Week 4, 12, 26, 40, 52). The Total score range is from 0 to 100 (0=Best, 100=Worst); lower scores correspond to better health. SGRQ questionnaire was completed by the patient at all study visits (Week 0 baseline, 4, 12, 26, 40, 52).

Time frame:
Baseline (Week 0), Week 4, 12, 26, 40, 52.
Reported as:
Least squares mean · score on a scale
11a_Change From Baseline in Saint George's Respiratory Questionnaire (SGRQ) -- at All Study Visits: Total Score
score on a scaleCHF 5993 pMDICHF 1535 pMDI Foster®
Week 4-3.66 (-4.41 to -2.91)-2.19 (-2.96 to -1.43)
Week 12-4.70 (-5.58 to -3.81)-2.66 (-3.55 to -1.77)
Week 26-4.76 (-5.69 to -3.83)-3.43 (-4.38 to -2.47)
Week 40-5.48 (-6.49 to -4.47)-4.08 (-5.11 to -3.05)
Week 52-5.12 (-6.18 to -4.06)-3.43 (-4.51 to -2.35)
Statistical analysis
  • CHF 5993 pMDI vs CHF 1535 pMDI Foster® · Linear Mixed Model for Repeated Measures · p = = 0.007 · Adjusted mean difference: -1.47 · 95% CI -2.54 to -0.39
  • CHF 5993 pMDI vs CHF 1535 pMDI Foster® · Linear Mixed Model for Repeated Measures · p = = 0.002 · Adjusted mean difference: -2.04 · 95% CI -3.30 to -0.78
  • CHF 5993 pMDI vs CHF 1535 pMDI Foster® · Linear Mixed Model for Repeated Measures · p = = 0.051 · Adjusted mean difference: -1.33 · 95% CI -2.66 to 0.01
  • CHF 5993 pMDI vs CHF 1535 pMDI Foster® · Linear Mixed Model for Repeated Measures · p = = 0.057 · Adjusted mean difference: -1.40 · 95% CI -2.85 to 0.04
  • CHF 5993 pMDI vs CHF 1535 pMDI Foster® · Linear Mixed Model for Repeated Measures · p = = 0.029 · Adjusted mean difference: -1.69 · 95% CI -3.20 to -0.17
Secondary11b_Change From Baseline in Saint George's Respiratory Questionnaire (SGRQ) -- at All Study Visits: Symptoms Score

Change from baseline in Saint George's respiratory questionnaire (SGRQ) -- Symptoms Score. SGRQ is a questionnaire developed to measure health in chronic airflow limitation. SGRQ questionnaire was completed by the patient at all study visits (Week 0 baseline, 4, 12, 26, 40, 52). Result show the Saint George's Respiratory Questionnaire (SGRQ) as change from baseline for the domain Symptoms. The Symptoms score is calculated on a scale of 0 to 100. A score of 0 indicates no impairment (best health); a score of 100 indicates the worst possible health status.

Time frame:
Baseline (Week 0), Week 4, 12, 26, 40, 52.
Reported as:
Least squares mean · score on a scale
11b_Change From Baseline in Saint George's Respiratory Questionnaire (SGRQ) -- at All Study Visits: Symptoms Score
score on a scaleCHF 5993 pMDICHF 1535 pMDI Foster®
Week 4-5.02 (-6.10 to -3.95)-3.83 (-4.92 to -2.75)
Week 12-5.09 (-6.29 to -3.89)-4.56 (-5.77 to -3.34)
Week 26-6.80 (-8.06 to -5.53)-5.17 (-6.46 to -3.88)
Week 40-8.35 (-9.73 to -6.96)-7.12 (-8.53 to -5.71)
Week 52-8.22 (-9.67 to -6.77)-7.26 (-8.74 to -5.78)
Statistical analysis
  • CHF 5993 pMDI vs CHF 1535 pMDI Foster® · Linear Mixed Model for Repeated Measures · p = = 0.126 · Adjusted mean difference: -1.19 · 95% CI -2.72 to 0.34
  • CHF 5993 pMDI vs CHF 1535 pMDI Foster® · Linear Mixed Model for Repeated Measures · p = = 0.54 · Adjusted mean difference: -0.53 · 95% CI -2.24 to 1.17
  • CHF 5993 pMDI vs CHF 1535 pMDI Foster® · Linear Mixed Model for Repeated Measures · p = = 0.077 · Adjusted mean difference: -1.63 · 95% CI -3.44 to 0.17
  • CHF 5993 pMDI vs CHF 1535 pMDI Foster® · Linear Mixed Model for Repeated Measures · p = = 0.224 · Adjusted mean difference: -1.23 · 95% CI -3.21 to 0.75
  • CHF 5993 pMDI vs CHF 1535 pMDI Foster® · Linear Mixed Model for Repeated Measures · p = = 0.364 · Adjusted mean difference: -0.96 · 95% CI -3.03 to 1.11
Secondary11c_Change From Baseline in Saint George's Respiratory Questionnaire (SGRQ) -- at All Study Visits: Impacts Score

Saint George's respiratory questionnaire (SGRQ) -- Impacts Score. SGRQ is a questionnaire developed to measure health in chronic airflow limitation. SGRQ questionnaire was completed by the patient at all study visits (Week 0 baseline, 4, 12, 26, 40, 52). Result show the Saint George's Respiratory Questionnaire (SGRQ) as change from baseline for the domain Impacts. The Impact score is calculated on a scale of 0 to 100. A score of 0 indicates no impairment (best health); a score of 100 indicates the worst possible health status.

Time frame:
Baseline (Week 0), Week 4, 12, 26, 40, 52.
Reported as:
Least squares mean · score on a scale
11c_Change From Baseline in Saint George's Respiratory Questionnaire (SGRQ) -- at All Study Visits: Impacts Score
score on a scaleCHF 5993 pMDICHF 1535 pMDI Foster®
Week 4-3.44 (-4.34 to -2.54)-2.29 (-3.20 to -1.38)
Week 12-4.65 (-5.69 to -3.62)-2.72 (-3.76 to -1.68)
Week 26-4.88 (-5.96 to -3.80)-3.50 (-4.60 to -2.39)
Week 40-5.33 (-6.45 to -4.20)-3.75 (-4.89 to -2.60)
Week 52-4.68 (-5.85 to -3.51)-2.59 (-3.79 to -1.40)
Statistical analysis
  • CHF 5993 pMDI vs CHF 1535 pMDI Foster® · Linear Mixed Model for Repeated Measures · p = = 0.077 · Adjusted mean difference: -1.15 · 95% CI -2.43 to 0.13
  • CHF 5993 pMDI vs CHF 1535 pMDI Foster® · Linear Mixed Model for Repeated Measures · p = = 0.01 · Adjusted mean difference: -1.93 · 95% CI -3.4 to -0.46
  • CHF 5993 pMDI vs CHF 1535 pMDI Foster® · Linear Mixed Model for Repeated Measures · p = = 0.079 · Adjusted mean difference: -1.39 · 95% CI -2.93 to 0.16
  • CHF 5993 pMDI vs CHF 1535 pMDI Foster® · Linear Mixed Model for Repeated Measures · p = = 0.054 · Adjusted mean difference: -1.58 · 95% CI -3.19 to 0.03
  • CHF 5993 pMDI vs CHF 1535 pMDI Foster® · Linear Mixed Model for Repeated Measures · p = = 0.015 · Adjusted mean difference: -2.09 · 95% CI -3.76 to -0.41
Secondary11d_Change From Baseline in Saint George's Respiratory Questionnaire (SGRQ) -- at All Study Visits: Activity Score

Saint George's respiratory questionnaire (SGRQ) -- Activity score. SGRQ is a questionnaire developed to measure health in chronic airflow limitation. SGRQ questionnaire was completed by the patient at all study visits (Week 0 baseline, 4, 12, 26, 40, 52). Result show the Saint George's Respiratory Questionnaire (SGRQ) as change from baseline for the domain Activity. The Activity score is calculated on a scale of 0 to 100. A score of 0 indicates no impairment (best health); a score of 100 indicates the worst possible health status.

Time frame:
Baseline (Week 0), Week 4, 12, 26, 40, 52.
Reported as:
Least squares mean · score on a scale
11d_Change From Baseline in Saint George's Respiratory Questionnaire (SGRQ) -- at All Study Visits: Activity Score
score on a scaleCHF 5993 pMDICHF 1535 pMDI Foster®
Week 4-2.69 (-3.65 to -1.73)-1.21 (-2.18 to -0.24)
Week 12-3.93 (-5.03 to -2.83)-1.35 (-2.46 to -0.24)
Week 26-3.88 (-5.01 to -2.75)-2.17 (-3.33 to -1.02)
Week 40-4.35 (-5.54 to -3.15)-2.74 (-3.96 to -1.51)
Week 52-4.26 (-5.49 to -3.02)-2.95 (-4.21 to -1.68)
Statistical analysis
  • CHF 5993 pMDI vs CHF 1535 pMDI Foster® · Linear Mixed Model for Repeated Measures · p = = 0.034 · Adjusted mean difference: -1.48 · 95% CI -2.84 to -0.11
  • CHF 5993 pMDI vs CHF 1535 pMDI Foster® · Linear Mixed Model for Repeated Measures · p = = 0.001 · Adjusted mean difference: -2.57 · 95% CI -4.14 to -1.01
  • CHF 5993 pMDI vs CHF 1535 pMDI Foster® · Linear Mixed Model for Repeated Measures · p = = 0.039 · Adjusted mean difference: -1.71 · 95% CI -3.33 to -0.09
  • CHF 5993 pMDI vs CHF 1535 pMDI Foster® · Linear Mixed Model for Repeated Measures · p = = 0.065 · Adjusted mean difference: -1.61 · 95% CI -3.32 to -0.10
  • CHF 5993 pMDI vs CHF 1535 pMDI Foster® · Linear Mixed Model for Repeated Measures · p = = 0.145 · Adjusted mean difference: -1.31 · 95% CI -3.08 to 0.45
Secondary12_Number of Participants With Saint George's Respiratory Questionnaire (SGRQ) Response (Change From Baseline in Total Score ≤-4) -- at Week 26 and Week 52

Number of participants with Saint George's Respiratory Questionnaire (SGRQ) response, defined as a change from baseline in SGRQ total score ≤ -4, at Week 26 and Week 52. If the change from baseline was \> -4, the patient was assessed as a non-responder in terms of SGRQ. Patients with missing change from baseline at the pre-specified tested time points were also classified as non-responders. Results shown represent the number of responder participants in terms of SGRQ, for the comparison of CHF 5993 pMDI versus CHF 1535 pMDI.

Time frame:
Baseline (Week 0), Week 26, Week 52.
Reported as:
Count of participants · Participants
12_Number of Participants With Saint George's Respiratory Questionnaire (SGRQ) Response (Change From Baseline in Total Score ≤-4) -- at Week 26 and Week 52
ParticipantsCHF 5993 pMDICHF 1535 pMDI Foster®
Week 26321246
Week 52297244
Statistical analysis
  • CHF 5993 pMDI vs CHF 1535 pMDI Foster® · Logistic model · p = < 0.001 · Odds ratio (or): 1.521 · 95% CI 1.211 to 1.911
  • CHF 5993 pMDI vs CHF 1535 pMDI Foster® · Logistic model · p = = 0.014 · Odds ratio (or): 1.327 · 95% CI 1.06 to 1.661
Secondary13a_Change From Baseline for Percentage of Days Without Intake of Rescue Medication -- Over Entire Treatment Period (52 Weeks of Treatment)

Days WITHOUT intake of rescue medication. Change from baseline to each inter-visit period and for the entire treatment period (Week 1-52) in the percentage of days without intake of rescue medication.

Time frame:
Baseline (Week 0) to Week 4, 12, 26, 40, 52.
Reported as:
Least squares mean · percentage of days
13a_Change From Baseline for Percentage of Days Without Intake of Rescue Medication -- Over Entire Treatment Period (52 Weeks of Treatment)
percentage of daysCHF 5993 pMDICHF 1535 pMDI Foster®
Week 1-46.67 (4.89 to 8.44)2.46 (0.67 to 4.25)
Week 5-126.23 (4.19 to 8.27)3.18 (1.12 to 5.24)
Week 13-265.49 (3.30 to 7.67)2.40 (0.19 to 4.60)
Week 27-404.39 (2.07 to 6.72)2.79 (0.43 to 5.15)
Week 41-523.82 (1.45 to 6.19)1.24 (-1.17 to 3.65)
Week 1-525.01 (3.05 to 6.98)2.36 (0.37 to 4.35)
Statistical analysis
  • CHF 5993 pMDI vs CHF 1535 pMDI Foster® · Linear Mixed Model for Repeated Measures · p = = 0.001 · Adjusted mean difference: 4.21 · 95% CI 1.69 to 6.73
  • CHF 5993 pMDI vs CHF 1535 pMDI Foster® · Linear Mixed Model for Repeated Measures · p = = 0.039 · Adjusted mean difference: 3.05 · 95% CI 0.15 to 5.95Week 5-12; Adjusted mean difference btw treat groups.
  • CHF 5993 pMDI vs CHF 1535 pMDI Foster® · Linear Mixed Model for Repeated Measures · p = = 0.051 · Adjusted mean difference: 3.09 · 95% CI -0.02 to 6.20
  • CHF 5993 pMDI vs CHF 1535 pMDI Foster® · Linear Mixed Model for Repeated Measures · p = = 0.342 · Adjusted mean difference: 1.60 · 95% CI -1.71 to 4.91
  • CHF 5993 pMDI vs CHF 1535 pMDI Foster® · Linear Mixed Model for Repeated Measures · p = = 0.134 · Adjusted mean difference: 2.59 · 95% CI -0.80 to 5.97
  • CHF 5993 pMDI vs CHF 1535 pMDI Foster® · Linear Mixed Model for Repeated Measures · p = = 0.063 · Adjusted mean difference: 2.65 · 95% CI -0.14 to 5.45
Secondary13b_Change From Baseline for the Average Use of Rescue Medication -- Over Entire Treatment Period (52 Weeks of Treatment)

Average use of rescue medication, over the entire treatment period (52 Weeks of treatment). Change from baseline to each inter-visit period and for the entire treatment period (Week 1-52) in the average use of rescue medication (number of puffs/day).

Time frame:
Baseline (Week 0) to Week 4, 12, 26, 40, 52.
Reported as:
Least squares mean · puffs/day
13b_Change From Baseline for the Average Use of Rescue Medication -- Over Entire Treatment Period (52 Weeks of Treatment)
puffs/dayCHF 5993 pMDICHF 1535 pMDI Foster®
Week 1-4-0.29 (-0.38 to -0.20)-0.07 (-0.17 to 0.02)
Week 5-12-0.25 (-0.36 to -0.14)-0.06 (-0.17 to 0.05)
Week 13-26-0.21 (-0.32 to -0.09)-0.02 (-0.14 to 0.10)
Week 27-40-0.09 (-0.22 to 0.04)0.02 (-0.11 to 0.15)
Week 41-52-0.04 (-0.17 to 0.09)0.07 (-0.07 to 0.21)
Week 1-52-0.15 (-0.26 to -0.04)0.00 (-0.11 to 0.12)
Statistical analysis
  • CHF 5993 pMDI vs CHF 1535 pMDI Foster® · Linear Mixed Model for Repeated Measures · p = = 0.001 · Adjusted mean difference: -0.21 · 95% CI -0.34 to -0.08
  • CHF 5993 pMDI vs CHF 1535 pMDI Foster® · Linear Mixed Model for Repeated Measures · p = = 0.016 · Adjusted mean difference: -0.19 · 95% CI -0.35 to -0.04
  • CHF 5993 pMDI vs CHF 1535 pMDI Foster® · Linear Mixed Model for Repeated Measures · p = = 0.029 · Adjusted mean difference: -0.19 · 95% CI -0.35 to -0.02
  • CHF 5993 pMDI vs CHF 1535 pMDI Foster® · Linear Mixed Model for Repeated Measures · p = = 0.225 · Adjusted mean difference: -0.11 · 95% CI -0.29 to 0.07
  • CHF 5993 pMDI vs CHF 1535 pMDI Foster® · Linear Mixed Model for Repeated Measures · p = = 0.262 · Adjusted mean difference: -0.11 · 95% CI -0.30 to 0.08
  • CHF 5993 pMDI vs CHF 1535 pMDI Foster® · Linear Mixed Model for Repeated Measures · p = = 0.062 · Adjusted mean difference: -0.15 · 95% CI -0.31 to 0.01
Secondary14_Rate of Moderate and Severe Chronic Obstructive Pulmonary Disease (COPD) Exacerbation Rate -- Over Entire Treatment Period (52 Weeks of Treatment)

Rate of moderate AND severe COPD exacerbations over the entire treatment period of treatment (52 weeks). COPD=Chronic obstructive pulmonary disease

Time frame:
Baseline (Week 0) to Week 52 (entire treatment period).
Reported as:
Least squares mean · events per patient per year
14_Rate of Moderate and Severe Chronic Obstructive Pulmonary Disease (COPD) Exacerbation Rate -- Over Entire Treatment Period (52 Weeks of Treatment)
events per patient per yearCHF 5993 pMDICHF 1535 pMDI Foster®
14_Rate of Moderate and Severe Chronic Obstructive Pulmonary Disease (COPD) Exacerbation Rate -- Over Entire Treatment Period (52 Weeks of Treatment)0.410 (0.358 to 0.469)0.530 (0.468 to 0.600)
Statistical analysis
  • CHF 5993 pMDI vs CHF 1535 pMDI Foster® · Negative binomial model · p = = 0.005 · Adjusted rate ratio: 0.773 · 0.773% CI 0.647 to 0.924
Secondary15_First Occurrence of All Moderate or Severe Chronic Obstructive Pulmonary Disease (COPD) Exacerbation

First occurrence of at least 1 moderate OR severe COPD exacerbation. First occurrence was analysed by Cox regression as time to first exacerbation and reported as hazard ratio. COPD=Chronic obstructive pulmonary disease

Time frame:
Baseline (Week 0), Week 52.
Reported as:
Number · number of first occurrences
15_First Occurrence of All Moderate or Severe Chronic Obstructive Pulmonary Disease (COPD) Exacerbation
number of first occurrencesCHF 5993 pMDICHF 1535 pMDI Foster®
15_First Occurrence of All Moderate or Severe Chronic Obstructive Pulmonary Disease (COPD) Exacerbation214240
Statistical analysis
  • CHF 5993 pMDI vs CHF 1535 pMDI Foster® · Cox proportional hazards analysis · p = 0.02 (Analysis is based on a Cox proportional hazards model including treatment, Country, number of COPD exacerbations in the previous year, severity of airflow limitation and smoking status at screening as factors.) · Hazard ratio (hr): 0.803 · 95% CI 0.668 to 0.967

Adverse events

Collected over Adverse events (AE) were reported from the time of patient informed consent signature until subject's study participation ended (Week 52 or early withdrawal).. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Beclometasone/Formoterol/Glycopyrrolate15/687 (2.2%)106/687 (15.4%)181/687 (26.3%)
Beclometasone/Formoterol16/680 (2.4%)123/680 (18.1%)203/680 (29.9%)
Most frequent serious events
Showing 10 of 110
Most frequent serious events
EventBeclometasone/Formoterol/GlycopyrrolateBeclometasone/Formoterol
Chronic obstructive pulmonary diseaseRespiratory, thoracic and mediastinal disorders66/68775/680
PneumoniaInfections and infestations14/6876/680
Myocardial ischaemiaCardiac disorders0/6874/680
Cardiac failureCardiac disorders4/6873/680
Acute myocardial infarctionCardiac disorders0/6873/680
Myocardial infarctionCardiac disorders1/6873/680
Lung neoplasm malignantNeoplasms benign, malignant and unspecified (incl cysts and polyps)3/6871/680
Atrial fibrillationCardiac disorders3/6871/680
Lung cancer metastaticNeoplasms benign, malignant and unspecified (incl cysts and polyps)1/6872/680
Sudden deathGeneral disorders0/6872/680
Most frequent other events
Most frequent other events
EventBeclometasone/Formoterol/GlycopyrrolateBeclometasone/Formoterol
Chronic obstructive pulmonary diseaseRespiratory, thoracic and mediastinal disorders159/687184/680
NasopharyngitisInfections and infestations39/68738/680

Baseline characteristics

Safety population: all randomised patients who received at least one dose of the study treatment. One patient in the CHF 1535 pMDI group did not use the study medication kit provided at V2 and withdrew consent a few days after the visit.

Age, Continuous
Age, Continuous(years)CHF 5993 pMDI Beclometasone/Formoterol/GlycopyrrolateCHF 1535 pMDI Foster® Beclometasone/FormoterolTotal
Mean63.3 ± 7.963.8 ± 8.263.6 ± 8.1
Age, Customized
Age, Customized(Participants)CHF 5993 pMDI Beclometasone/Formoterol/GlycopyrrolateCHF 1535 pMDI Foster® Beclometasone/FormoterolTotal
Adults (<65 years)391347738
Adults (≥65 years to 74 years)237266503
Adults (≥75)5967126
Sex: Female, Male
Sex: Female, Male(Participants)CHF 5993 pMDI Beclometasone/Formoterol/GlycopyrrolateCHF 1535 pMDI Foster® Beclometasone/FormoterolTotal
Female178153331
Male5095271036
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)CHF 5993 pMDI Beclometasone/Formoterol/GlycopyrrolateCHF 1535 pMDI Foster® Beclometasone/FormoterolTotal
Other314
White6846791363
Region of Enrollment
Region of Enrollment(participants)CHF 5993 pMDI Beclometasone/Formoterol/GlycopyrrolateCHF 1535 pMDI Foster® Beclometasone/FormoterolTotal
Argentina282553
Belgium437
Bulgaria464692
Czechia104104208
Germany313263
Hungary5251103
Italy111223
Mexico314
Poland5756113
Romania5352105
Russia160159319
Slovakia151833
Ukraine113111224
United Kingdom101020
Time since first COPD diagnosis (years
Time since first COPD diagnosis (years(years)CHF 5993 pMDI Beclometasone/Formoterol/GlycopyrrolateCHF 1535 pMDI Foster® Beclometasone/FormoterolTotal
Mean7.71 ± 5.757.67 ± 5.987.69 ± 5.87
Main COPD phenotype
Main COPD phenotype(Participants)CHF 5993 pMDI Beclometasone/Formoterol/GlycopyrrolateCHF 1535 pMDI Foster® Beclometasone/FormoterolTotal
Chronic bronchitis only336332668
Emphysema only220197417
Chronic bronchitis and emphysema114131245
Unknown172037
Number of COPD exacerbations in the previous year
Number of COPD exacerbations in the previous year(Participants)CHF 5993 pMDI Beclometasone/Formoterol/GlycopyrrolateCHF 1535 pMDI Foster® Beclometasone/FormoterolTotal
1 Exacerbation5515461097
2 Exacerbations116114230
3 Exacerbations171734
>3 Exacerbations336

4 further baseline measures are reported on the registry.

08

Study locations

1 site
  • Dr Beatrix BALINT
    Szeged, 6722, Hungary
09

References and documents

Publications

  • Vanfleteren L, Fabbri LM, Papi A, Petruzzelli S, Celli B. Triple therapy (ICS/LABA/LAMA) in COPD: time for a reappraisal. Int J Chron Obstruct Pulmon Dis. 2018 Dec 12;13:3971-3981. doi: 10.2147/COPD.S185975. eCollection 2018. PubMed 30587953 ↗
  • Singh D, Fabbri LM, Vezzoli S, Petruzzelli S, Papi A. Extrafine triple therapy delays COPD clinically important deterioration vs ICS/LABA, LAMA, or LABA/LAMA. Int J Chron Obstruct Pulmon Dis. 2019 Feb 28;14:531-546. doi: 10.2147/COPD.S196383. eCollection 2019. PubMed 30880943 ↗
  • Singh D, Fabbri LM, Corradi M, Georges G, Guasconi A, Vezzoli S, Petruzzelli S, Papi A. Extrafine triple therapy in patients with symptomatic COPD and history of one moderate exacerbation. Eur Respir J. 2019 May 18;53(5):1900235. doi: 10.1183/13993003.00235-2019. Print 2019 May. PubMed 30792343 ↗
  • Singh D, Papi A, Corradi M, Pavlisova I, Montagna I, Francisco C, Cohuet G, Vezzoli S, Scuri M, Vestbo J. Single inhaler triple therapy versus inhaled corticosteroid plus long-acting beta2-agonist therapy for chronic obstructive pulmonary disease (TRILOGY): a double-blind, parallel group, randomised controlled trial. Lancet. 2016 Sep 3;388(10048):963-73. doi: 10.1016/S0140-6736(16)31354-X. Epub 2016 Sep 1. PubMed 27598678 ↗

Individual participant data

Plan to share: Yes — Chiesi clinical data sharing scope, process and data access criteria is available on the Chiesi Group website.

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Mar 2014 to primary completion in Jan 2016, 21 months.

Results were first posted in Jun 2026, 10 years 4 months after primary completion.

Of 108 industry-sponsored phase 3 interventional studies under Pulmonary Disease, Chronic Obstructive, half reached primary completion within 20 months of starting (the median), counting those still running; a quarter within 13 and three quarters within 36. This study's 21 months is close to that.

Counting every sponsor, half of 141 studies reached it within 23 months; a quarter within 14 and three quarters within 44.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 5, 2013
First posted
Aug 6, 2013
StartActual
Mar 21, 2014
Primary completionActual
Jan 14, 2016
CompletionActual
Jan 14, 2016
Results first posted
Jun 3, 2026
Last update
Jul 20, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 20, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT01917331
Responsible party
Sponsor
First posted
Aug 6, 2013
Start date
Mar 21, 2014
Primary completion
Jan 14, 2016
Completion
Jan 14, 2016
Results posted
Jun 3, 2026
Last update
Jul 20, 2026

Study contacts

Dave SINGH, MD
principal investigator · University Hospital of South Manchester, MANCHESTER M23 9 QZ, UK

Oversight

Data monitoring committee
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jun 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Beclomethasone · Formoterol · Glycopyrrolate

Start the discussion